natgillin/translations-raw huggingface dataset:
Kidney disease patients There is no experience with subcutaneous use (injection into the skin) of Silapo in kidney patients.
Neeruhaigusega patsiendid Ei ole palju kogemusi Silapo nahaaluse kasutamisega (süstimine naha alla) neeruhaigusega patsientidel.
Therefore, if you are being treated for anaemia associated with kidney disease, Silapo has to be given by injection into a vein (intravenously).
Seetõttu peab neeruhaigusest tingitud aneemia ravil manustama Silapot veenisüstidega (intravenoosselt).
PRCA
Punavereliblede aplaasia võib olla põhjustatud
185 may be caused by the production to antibodies against the erythropoietin product and, in the following, to your own erythropoietin.
185 antikehade tekkimisest vastureaktsioonina erütropoetiinile ja sealjuures ka organismi enda erütropoetiinile.
If PRCA, a very rare condition, occurs, the Silapo therapy will be stopped and your doctor will determine the best course of action to treat the anaemia.
Juhul, kui PRCA - küll harva – ilmneb, peab peatama ravi Silapoga ja teie arst leiab parima sobiva ravi aneemia vastu.
Although this complication is very rare, you should be aware that if you develop it, you would need to have regular blood transfusions, possibly lifelong, to treat your anaemia and the Silapo therapy would have to be discontinued.
Kuigi antud komplikatsioon on harv, peate te olema teadlik, et kui see ilmneb, vajate te regulaarseid vereülekandeid, võimalik, et eluaegset aneemia ravi ning Silapo ravi katkestatakse.
If you are receiving dialysis treatment when you begin treatment with Silapo, your dialysis regimen may need to be adjusted to maintain urea, creatinine and potassium levels in the desired range.
Juhul, kui saate dialüüsi Silopo ravi alustamise ajal, võib teie dialüüsi ettekirjutus vajada korrigeerimist, et hoida uurea, kreatiniini ja kaaliumi taset soovitud vahemikus.
An increase in the dose of a particular blood-thinning medicine (heparin) during haemodialysis is often needed during the course of therapy with Silapo to minimize the risk of blood clotting.
Verd vedeldavate medikamentide (hepariin) annuse suurendamine hemodialüüsi korral on tihti vajalik Silapo ravil, et vähendada vereklompide tekkimise riski.
Cancer patients Cancer patients are more likely to suffer from blood clots if receiving erythropoietin medicines, like Silapo (see section 4).
Vähihaiged patsiendid Vähihaigetel patsientidel on rohkem eeldusi veretrombide tekkimisele saades erütropoetiini põhiseid medikamente nagu Silapo (vt lõik 4).
If you are a cancer patient, you should be aware that Silapo may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer.
Juhul kui olete vähihaige patsient, peate olema teadlik, et Silapo, võib toimida vererakkude kasvufaktorina ja teatud tingimustes võib omada negatiivset mõju teie vähile.
In particular, if you are taking a medicine containing the active substance ciclosporin to suppress your immune system after a kidney transplant, your doctor may order special blood tests to measure ciclosporin levels while you are taking Silapo.
Eriti juhul, kui te tarvitate ravimit, mis sisaldab toimeainet tsüklosporiin, et pidurdada immuunsüsteemi tööd peale neeru siirdamist, peab teie arst tegema spetsiaalsed vereproovid tsüklosporiinitaseme mõõtmiseks Silapo tarvitamise ajal.
186 Pregnancy and breast-feeding
186 Rasedus ja imetamine
Tell your doctor if you are pregnant or think you may be pregnant or are breast-feeding.
Informeerige oma arsti, kui te olete rase või arvate, et võite olla rase, või toidate last rinnaga.
If you are pregnant or breast-feeding, Silapo should be used only if the potential benefit outweighs the potential risk to the foetus.
Juhul, kui te olete rase või toidate last rinnaga, võib Silapot tarvitada ainult juhul, kui potentsiaalne kasu kaalub üles riski lootele.
Important information about some of the ingredients of Silapo
Oluline teave mõningate Silapo koostisainete suhtes
HOW TO USE SILAPO
KUIDAS SILAPOT KASUTADA
Silapo therapy is usually started under medical supervision.
Silapo ravi algab tavaliselt meditsiinilise järelvalve all.
In case Silapo is injected under the skin (subcutaneously) you can also inject the solution yourself once you have been shown how.
Juhul, kui Silapot süstitakse naha alla, saate Te ise seda süstida, kui Teile on ettenäidatud, kuidas seda teha.
Always use Silapo exactly as your doctor has told you.
Kasutage Silapot alati täpselt nii, nagu arst on teile rääkinud.
Your doctor will conduct investigations, for example blood tests, to help decide if it is necessary for you to have Silapo.
Teie arst viib läbi uuringud, näiteks vereproovid, et selgitada välja, kas teil on vajalik tarvitada Silapot.
Silapo may be given during the dialysis session or after you have received a dialysis session.
Silapot võib manustada dialüüsi sessooni ajal või peale selle lõppu.
The usual starting dose of Silapo is 50 IU/kg (International Units per kilogram).
Tavaline Silapo algdoos on 50 IU/ kg (rahvusvahelist ühikut kilogrammi kohta).
When your condition has been brought under control, you will receive regular doses of Silapo, 2 or 3 times a week.
Kui teie seisund on jõudnud kontrolli alla, hakkate te saama Silapo regulaarseid doose 2 või 3 kord nädalas.
Silapo should be given after the patient has received a dialysis session.
Silapot peab manustama lapsele peale dialüüsi sessooni saamist.
187 The dose for children and adolescents is based on body weight in kilograms.
187 Lastele ja noorukitele manustatava annuse aluseks on kehakaal kilogrammides.
The usual starting dose is 50 IU/ kg.
Tavaline algdoos on 50 IU/ kg.
Depending on how the anaemia responds, the dose may be adjusted approximately every 4 weeks until the condition is controlled.
Sõltuvalt aneemia reageerimisest ravile võib doosi korrigeerida iga 4 nädala järel.
Use in adult patients with kidney disease but not receiving dialysis The usual starting dose is 50 IU/kg.
Tarvitamine täiskasvanud neeruhaigusega patsientidel, kes ei saa dialüüsi Tavaline algdoos on 50 IU/ kg.
After your condition has been brought under control, you will receive regular doses of Silapo, 3 times a week.
Pärast seda saate Silapot 3 korda nädalas.
Use in adult patients receiving chemotherapy Your doctor may initiate treatment with Silapo if your haemoglobin level is 10 g/dl or less.
Tarvitamine täiskasvanud kemoteraapiat saavatel patsientidel Teie arst võib alustada Silapo ravi, kui teie hemoglobiini tase on 10 g/ dl või vähem.
The starting dose may be adjusted by your doctor depending on how your anaemia responds to treatment; you will usually receive Silapo until 1 month after the end of chemotherapy.
Algdoosi võib korrigeerida sõltuvalt sellest kuidas aneemia allub ravile; tavaliselt saate Silapot kuni 1 kuu peale kemoteraapia lõppu.
You will receive Silapo during the 3 weeks before your surgery.
Te saate Silapot 3 nädala jooksul enne kirurgiat.
You will also take iron supplements before and during Silapo treatment to increase the effectiveness of Silapo.
Ravi efektiivsuse suurendamiseks saate te ka lisarauda enne Silapo ravi ja ja ravi ajal.
Silapo must not be shaken or mixed with any other liquid.
Silapot ei tohi segada muude injektsiooni vedelikega.
If Silapo is injected under the skin for anaemia not associated with kidney disease the amount injected in any one place should not exceed 1 ml.
Juhul, kui Silapot süstitakse naha alla aneemia puhul, mis ei ole seotud neeruhaigustega, ei tohi süstitav kogus ühte kohta ületada 1 ml.
Always follow these instructions when using Silapo:
Järgige alati käesolevaid instruktsioone, kui kasutate Silapot:
Do not use Silapo if:
Ärge kasutage Silapot juhul, kui:
Changing from injecting into a vein to injecting under the skin (from intravenous into subcutaneous injection) Once your condition is controlled you will receive regular doses of Silapo.
Intravenoosse injektsiooni vahetamine nahaaluse injektsiooni vastu Kui teie seisund on kontrollitud, hakkate te saama regulaarseid Silapo doose.
If your anaemia is not associated with kidney disease, your doctor may decide that it is better for you to receive Silapo by injection under the skin (subcutaneous) rather than into a vein (intravenous).
Juhul, kui teie aneemia ei ole seotud neeruhaigusega, võib arst otsustada, et on parem saada Silapot nahaaluse injektsiooniga, mitte intravenoosselt.
Injecting Silapo under the skin yourself for anaemia not associated with kidney disease At the start of your therapy, Silapo is injected by medical or nursing staff.
Silapo süstimine ise naha alla neeruhaigusega mitteseotud aneemia korral Ravi algul peab Silapot süstima meditsiinitöötaja.
However, your doctor may decide that it is right for you to learn how to inject Silapo under the skin (subcutaneously) yourself.
Samas võib arst otsustada, et teil on parem õppida, kuidas ise Silapot naha alla süstida.
If you use more Silapo than you should
Kui te kasutate Silapot rohkem kui ette nähtud
Silapo has a wide safety margin and side effects due to an overdose of using Silapo are unlikely.
Silapol on lai ohutuse piir ja üledoosiga kõrvalmõjud on ebatõenäolised.
You should inform the doctor or nurse immediately if you think too much Silapo has been injected.
Informeerige oma arsti või põetajat koheselt kui arvate, et olete saanud liiga palju Silapot.
If you forget to use Silapo
Kui te unustate Silapot manustada
If you stop using Silapo Do not to stop the treatment without consultation of your doctor.
Ärge katkestage ravi ilma et oleksite konsulteerinud arstiga.
Like all medicines, Silapo can cause side effects, although not everybody gets them.
Nagu kõik ravimid, võib ka Silapo põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
189 – skin rash – flu-like symptoms, such as headache, aches and pains in the joints, feeling of weakness, tiredness, dizziness.
189 häireid, nt häiritud südame vereringe, südameatakk,, aju hemorraagia, ajurabandus, ajuvereringe ajutine häirumine, süvaveenitromboos, arterite tromboos, kopsuarteri emboolia, veresoonte seina dilatatsioon (aneurüsm), reetina tromboos ja kunstneeru tromboseerumine.
These may be more common at the start of treatment. – An increase in levels of blood platelets (thrombocytes) which are normally involved in the formation of a blood clot may occur.
silmalaugude ja huulte piirkonnas (Quincke’ i ödeem) ja šokilaadseid allergilisi reaktsioone, millega kaasneb surisev tunne, punetus, sügelus, kuumahood ja kiirenenud pulss.
Your doctor will check on this. – Vascular and thrombotic events (blood clotting) in blood vessels, such as disturbed blood perfusion of the heart, heart attack, cerebral haemorrhages, stroke, temporary disturbance of blood perfusion in the brain, deep vein thrombosis, arterial thrombosis, pulmonary embolism, dilatation of the wall of a blood vessel (aneurysm), retinal thrombosis, and blood clot in an artificial kidney have been reported in patients receiving erythropoietin treatment. – Hypersensitivity reactions have been reported in rare cases, including swelling, mainly in the region of the eyelids and the lips (Quincke's oedema) and shock-like allergic reactions with symptoms of tingling, reddening, itching, hot flush and accelerated pulse. – Pure red cell aplasia (PRCA) has been very rarely reported in patients after months to years of subcutaneous (injection under the skin) erythropoietin treatment.
PRCA tähendab võimetust toota luuüdis piisavalt punaseid vereliblesid (vt lõik „ Eriline ettevaatus on vajalik ravimiga Silapo ”).
PRCA means the inability to produce enough red blood cells in the bone (see section “Take special care with Silapo”).
- Kõrgenenud vererõhu korral võib olla vajalik medikamentoosne ravi või nende ravimite
Kidney patients – raised blood pressure which may require treatment with medicinal products or adjustment of the dosage of medicinal products you already take for high blood pressure.
Teie arst võib Silapo kasutamise ajal regulaarselt jälgida vererõhku, eriti ravi alguses.
Your doctor may monitor your blood pressure regularly while you are using Silapo, particularly at the start of therapy. – Occlusion in the connection between artery and vein (shunt thrombosis) may occur especially if you have low blood pressure or if your arteriovenous fistula has complications.
- Tekkida võib ummistus arteri ja veeni ühenduskohas (šundi tromboos), eriti juhul, kui teil on
Your doctor may check your shunt and prescribe a medicinal product to prevent thrombosis.
madal vererõhk või kui teil on tüsistunud arteriovenoosne fistul.
Cancer patients – blood clotting (thrombotic vascular events) (see section “Take special care with Silapo”). – increase of blood pressure.
- Vere tromboseerumine (trombootiline vaskulaarne tüsistus) (vt lõik „ Eriline ettevaatus on
HOW TO STORE SILAPO
KUIDAS SILAPOT SÄILITADA
Do not use Silapo after the expiry date which is stated on the label and the carton.
Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud sildil ja karbil pärast {kuupäev EXP}.
The syringe can be removed from the refrigerator and left at room temperature for a single period of maximum 3 days (but not above 25°C).
Ravimeid ei tohi ära visata kanalisatsiooni kaudu ega koos majapidamisprügiga.
190 6.
6.
– The active substance is epoetin zeta (produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell line.
– Toimeaine on dzeetaepoetiin (toodetud recombinantse DNA tehnoloogiaga CHO rakuahelas).
Silapo 1000 IU/0.3ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.3 ml solution for injection contains 1000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 1000 IU/ 0, 3 ml lahus eeltäidetud süstlaga süstimiseks 1 eeltäidetud süstal 0, 3 ml süstimislahusega sisaldab 1000 rahvusvahelist ühikut (IU) dzeetaepoetiini (rekombinantne inimerütropoetiin).
Silapo 2000 IU/0.6ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.6 ml solution for injection contains 2000 international units (IU) epoetin zeta (recombinant human erythropoietin).
190 1 eeltäidetud süstal 0, 6 ml süstimislahusega sisaldab 2000 rahvusvahelist ühikut (IU) dzeetaepoetiini (rekombinantne inimerütropoetiin).
Silapo 3000 IU/0.9ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.9 ml solution for injection contains 3000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 3000 IU/ 0, 9 ml lahus eeltäidetud süstlaga süstimiseks 1 eeltäidetud süstal 0, 9 ml süstimislahusega sisaldab 3000 rahvusvahelist ühikut (IU) dzeetaepoetiini (rekombinantne inimerütropoetiin).
Silapo 4000 IU/0.4ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.4 ml solution for injection contains 4000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 4000 IU/ 0, 4 ml lahus eeltäidetud süstlaga süstimiseks 1 eeltäidetud süstal 0, 4 ml süstimislahusega sisaldab 4000 rahvusvahelist ühikut (IU) dzeetaepoetiini (rekombinantne inimerütropoetiin).
Silapo 5000 IU/0.5ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.5 ml solution for injection contains 5000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 5000 IU/ 0, 5 ml lahus eeltäidetud süstlaga süstimiseks 1 eeltäidetud süstal 0, 5 ml süstimislahusega sisaldab 5000 rahvusvahelist ühikut (IU) dzeetaepoetiini (rekombinantne inimerütropoetiin).
Silapo 6000 IU/0.6ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.6 ml solution for injection contains 6000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 6000 IU/ 0, 6 ml lahus eeltäidetud süstlaga süstimiseks 1 eeltäidetud süstal 0, 6 ml süstimislahusega sisaldab 6000 rahvusvahelist ühikut (IU) dzeetaepoetiini (rekombinantne inimerütropoetiin).
Silapo 8000 IU/0.8ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.8 ml solution for injection contains 8000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 8000 IU/ 0, 8 ml lahus eeltäidetud süstlaga süstimiseks 1 eeltäidetud süstal 0, 8 ml süstimislahusega sisaldab 8000 rahvusvahelist ühikut (IU) dzeetaepoetiini (rekombinantne inimerütropoetiin).
Silapo 10000 IU/1.0ml solution for injection in pre-filled syringe 1 pre-filled syringe with 1.0 ml solution for injection contains 10000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 10000 IU/ 1, 0 ml lahus eeltäidetud süstlaga süstimiseks 1 eeltäidetud süstal 1, 0 ml süstimislahusega sisaldab 10000 rahvusvahelist ühikut (IU) dzeetaepoetiini (rekombinantne inimerütropoetiin).
Silapo 20000 IU/0.5ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.5 ml solution for injection contains 20000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 20000 IU/ 0, 5 ml lahus eeltäidetud süstlaga süstimiseks 1 eeltäidetud süstal 0, 5 ml süstimislahusega sisaldab 20000 rahvusvahelist ühikut (IU) dzeetaepoetiini (rekombinantne inimerütropoetiin).
Silapo 30000 IU/0.75ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.75 ml solution for injection contains 30000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 30000 IU/ 0, 75 ml lahus eeltäidetud süstlaga süstimiseks 1 eeltäidetud süstal 0, 75 ml süstimislahusega sisaldab 30000 rahvusvahelist ühikut (IU) dzeetaepoetiini (rekombinantne inimerütropoetiin).
191 Silapo 40000 IU/1.0ml solution for injection in pre-filled syringe 1 pre-filled syringe with 1.0 ml solution for injection contains 40000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 40000 IU/ 1, 0 ml lahus eeltäidetud süstlaga süstimiseks 1 eeltäidetud süstal 1, 0 ml süstimislahusega sisaldab 40000 rahvusvahelist ühikut (IU) dzeetaepoetiini (rekombinantne inimerütropoetiin).
The other ingredients are disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, calcium chloride dihydrate, polysorbate 20, glycine, leucine, isoleucine, threonine, glutamic acid, phenylalanine, water for injections, sodium hydroxide (pH adjuster), hydrochloric acid (pH adjuster).
Abiained on naatriumdivesinikfosfaatdihüdraat, naatriumdihüdrogeenfosfaatdihüdraat, naatriumkloriid, kaltsiumkloriiddihüdraat, polüsorbaat 20, glütsiin, leutsiin, isoleutsiin, treoniin, glutamiinhape, fenüülalaniin, vesi lahuseks, naatriumhüdroksiid (pH reguleerimiseks), hüdrokloriidhape (pH reguleerimiseks).
Silapo is presented as a clear and colourless solution for injection in a pre-filled syringe with a fixed injection needle.
Sellega on täidetud läbipaistvad fikseeritud nõelaga klaassüstlad.
The pre-filled syringes contain between 0.3 and 1.0 ml solution, depending on the content of epoetin zeta (see “What Silapo contains”).
„ Mida Silapo sisaldab “).
cell pharm GmbH Theodor-Heuss-Str.
cell pharm GmbH Theodor- Heuss- Str.
52 D-61118 Bad Vilbel Tel: +49 (0) 6101 30 42 0 Fax: +49 (0) 6101 30 42 11
52 D- 61118 Bad Vilbel Tel: +49 (0) 6101 30 42 0 Fax: +49 (0) 6101 30 42 11
What is Silgard used for?
Milleks Silgardi kasutatakse?
Silgard is used to vaccinate against precancerous lesions (abnormal cell growth) in the genital area (cervix, vulva or vagina), cancer of the cervix and genital warts that are caused by infection with the human papillomavirus (HPV) types 6, 11, 16 or 18. The effectiveness of Silgard has been studied in women aged 16 to 26 years, and its immunogenicity (its ability to make the immune system respond to the viruses) has been studied in children and adolescents aged nine to 15 years.
Silgardi efektiivsust uuriti 16 – 26- aastastel täiskasvanud naistel ning selle immunogeensust (võimet panna immuunsüsteem viirustele reageerima) uuriti 9– 15- aastastel lastel ja noorukitel.
Silgard is given according to official recommendations.
Silgardi antakse ametlike soovituste kohaselt.
How is Silgard used?
Kuidas Silgardi kasutatakse?
Silgard is given to individuals aged nine years or over, as three doses, with two months between the first and second doses, and four months between the second and third doses.
Silgardi manustatakse 9- aastastele ja vanematele patsientidele kolme annusena, jättes esimese ja teise annuse vahele kaks kuud ning teise ja kolmanda annuse vahele neli kuud.
It is recommended that individuals who receive the first dose of Silgard should complete all three doses with Silgard.
Patsientidel, kes on saanud esimese Silgardi annuse, on soovitatav vaktsineerimine Silgardiga lõpuni viia.
All papillomaviruses have a shell, or ‘ capsid’, that is made up of proteins called ‘ L1 proteins’.
Igal papilloomiviirusel on kest ehk kapsiid, mis koosneb valkudest (L1 valgud).
Silgard contains the purified L1 proteins for four of the types of human papillomavirus: types 6, 11, 16, and 18.
Silgard sisaldab nelja tüüpi inimese papilloomiviiruste, tüüpide 6, 11, 16 ja 18 puhastatud L1 valke.
The proteins in Silgard are produced by a method known as ‘ recombinant DNA technology’: they are made by a yeast that has received a gene (DNA), which makes it able to produce the L1 proteins.
Need koondatakse viirusetaolisteks osakesteks (mis sarnanevad struktuurilt HPV viirusele, et keha need paremini ära tunneks).
They are assembled in ‘ virus-like particles’ (structures that look like HPV, so that the body can 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged. recognise them easily). The vaccine also contains an ‘ adjuvant ’ (a compound containing aluminium) to stimulate a better response.
Reproduction is authorised provided the source is acknowledged.
The antibodies help to block the virus from entering cells in the body.
Antikehad takistavad viiruse sisenemist keha rakkudesse.
How has Silgard been studied?
Kuidas Silgardi uuriti?
The effects of Silgard were first tested in experimental models before being studied in humans.
Enne uuringuid inimestel kontrolliti Silgardi toimet muude katsetega.
Silgard was compared with placebo (a dummy vaccine).
Silgardi võrreldi platseeboga (näiva vaktsiiniga).
Silgard was effective against precancerous genital lesions of the cervix, vulva and vagina, cervical cancer, and warts related to HPV types 6, 11, 16 and 18.
Silgard oli HPV tüüpidest 6, 11, 16 ja 18 tingitud suguelundite, st emakakaela häbeme ja tupe vähieelsete kahjustuste, emakakaela vähi ja suguelundite tüügaste vastase vaktsiinina efektiivne.
Looking at the results of all four studies together, in women who had never been infected by HPV types 6, 11, 16 or 18 before, and who received the full course of vaccination, one woman out of over 8,000 vaccinated with Silgard developed a precancerous lesion in the cervix that might have been due to HPV type 16 or 18.
Kõigi nelja uuringu kokkuvõttes tekkis ühel (enam kui 8000- st) Silgardiga vaktsineeritud naisel, kes ei olnud varem HPV tüüpidega 6, 11, 16 ja 18 nakatunud ning kes läbis täieliku vaktsineerimiskuuri, HPV tüüpidest 16 või 18 põhjustatud vähieelne emakakaela kahjustus.
A similar effect of Silgard was seen when the analysis also included lesions of the cervix due to the other two HPV types (types 6 and 11).
Samane Silgardi toime ilmnes ka HPV tüüpidest 6 ja 11 põhjustatud emakakaela kahjustuste analüüsimisel.
For external genital lesions due to HPV types 6, 11, 16 or 18 (including warts and precancerous lesions of the vulva or the vagina), the results of three of the studies were looked at together.
HPV tüüpidest 6, 11, 16 ja 18 põhjustatud välissuguelundite kahjustusi (sealhulgas tüükad ning vähieelsed tupe ja häbeme kahjustused) esines kolme uuringu tulemuste kokkuvõttes Silgardiga vaktsineeritud rühmas kahel naisel (ligikaudu 8000- st) suguelundite tüükaid.
Two women out of almost 8,000 in the Silgard group developed genital warts, and there were no cases of precancerous lesions of the vulva or the vagina.
Vähieelseid tupe ja häbeme kahjustusi ei esinenud.
In studies, the most common side effects with Silgard (seen in more than 1 patient in 10) were pyrexia (fever) and reactions at the site of the injection (redness, pain and swelling).
Uuringutes olid kõige sagedamad kõrvalnähud (esinenud enam kui ühel patsiendil kümnest) püreksia (palavik) ning reaktsioonid süstekohal (punetus, valu, paistetus).